Literature DB >> 20002703

CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.

T Maruyama1, K Kono, S Izawa, Yoshiki Mizukami, Y Kawaguchi, K Mimura, M Watanabe, H Fujii.   

Abstract

It has been reported that an increased population of regulatory T cells (T-regs) is one of the reasons for impaired anti-tumor immunity. We investigated the frequency of Foxp3(+) T-regs in tumor-infiltrating lymphocytes (TILs) and peripheral blood lymphocytes (PBLs) of patients with esophageal squamous cell carcinoma (ESCC). Furthermore, in order to elucidate the mechanisms behind T-regs accumulation within tumors, we evaluated the relationship between CCL17 or CCL22 expression and the frequency of Foxp3(+) T-regs. CD4(+)CD25(+)Foxp3(+) T-regs as a percentage of CD4(+) cells were counted by flow cytometry. The frequency of CCL17(+) or CCL22(+) cells among CD14(+) cells in tumors was also evaluated by flow cytometry. Moreover, an in vitro migration assay using T-regs derived from ESCC was performed in the presence of CCL17 or CCL22. The frequency of Foxp3(+) T-regs in TILs was significantly higher than that in the normal esophageal mucosa (24.6 +/- 10.0 vs 7.1 +/- 5.9%, P < 0.01). The frequency of Foxp3(+) T-regs in PBLs of ESCC patients was significantly higher than that in normal healthy donors (7.0 +/- 4.2 vs 2.5 +/- 1.0%, P < 0.01). Furthermore, the frequency of CCL17(+) or CCL22(+) cells among CD14(+) cells within tumors was significantly higher than that of normal esophageal mucosa, and there was a significant correlation between the frequency of CCL17(+) or CCL22(+) cells and Foxp3(+) T-regs in TILs. In addition, the in vitro migration assay indicated that T-regs were significantly induced to migrate by CCL17 or CCL22. In conclusion, CCL17 and CCL22 within the tumor are related to the increased population of Foxp3(+) T-regs in ESCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002703     DOI: 10.1111/j.1442-2050.2009.01029.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  34 in total

1.  Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.

Authors:  A Jafarzadeh; H Fooladseresht; K Minaee; M R Bazrafshani; A Khosravimashizi; M Nemati; M Mohammadizadeh; M M Mohammadi; A Ghaderi
Journal:  Tumour Biol       Date:  2014-10-22

2.  An imbalance between innate and adaptive immune cells at the maternal-fetal interface occurs prior to endotoxin-induced preterm birth.

Authors:  Marcia Arenas-Hernandez; Roberto Romero; Derek St Louis; Sonia S Hassan; Emily B Kaye; Nardhy Gomez-Lopez
Journal:  Cell Mol Immunol       Date:  2015-04-06       Impact factor: 11.530

Review 3.  Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.

Authors:  Adam W Mailloux; M Rita I Young
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

4.  Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Authors:  Liyanage P Perera; Meili Zhang; Masao Nakagawa; Michael N Petrus; Michiyuki Maeda; Marshall E Kadin; Thomas A Waldmann; Pin-Yu Perera
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

Review 5.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

6.  RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity.

Authors:  Hong Wang; Reading Ashton; Jonathan A Hensel; Joo Hyoung Lee; Vinayak Khattar; Yong Wang; Jessy S Deshane; Selvarangan Ponnazhagan
Journal:  Mol Cancer Ther       Date:  2020-11-16       Impact factor: 6.261

7.  Associations of circulating mediators of inflammation, cell regulation and immune response with esophageal squamous cell carcinoma.

Authors:  M Constanza Camargo; Minkyo Song; Hidemi Ito; Isao Oze; Yuriko N Koyanagi; Yumiko Kasugai; Charles S Rabkin; Keitaro Matsuo
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-14       Impact factor: 4.553

Review 8.  Suppression, subversion and escape: the role of regulatory T cells in cancer progression.

Authors:  K Oleinika; R J Nibbs; G J Graham; A R Fraser
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

9.  Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.

Authors:  Ya-Qing Li; Fang-Fang Liu; Xin-Min Zhang; Xiao-Jing Guo; Mei-Jing Ren; Li Fu
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

10.  CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.

Authors:  Peng Xu; XiaoLan Xu; Xiao Wu; LiXiang Zhang; Lei Meng; ZhangMing Chen; WenXiu Han; Jie Yao; AMan Xu
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.